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Abstract
We previously demonstrated that severe hypoxia inhibits growth of Chronic Myeloid Leukemia (CML) cells and selects stem
cells where BCR/Ablprotein is suppressed, although mRNA is not, so that hypoxia-selected stem cells, while remaining
leukemic, are independent of BCR/Abl signaling and thereby refractory to Imatinib-mesylate. The main target of this study
was to address the effects of the proteasome inhibitor Bortezomib (BZ) on the maintenance of stem or progenitor cells in
hypoxic primary cultures (LC1), by determining the capacity of LC1 cells to repopulate normoxic secondary cultures (LC2)
and the kinetics of this repopulation. Unselected K562 cells from day-2 hypoxic LC1 repopulated LC2 with rapid, progenitor-
type kinetics; this repopulation was suppressed by BZ addition to LC1 at time 0, but completely resistant to day-1 BZ,
indicating that progenitors require some time to adapt to stand hypoxia. K562 cells selected in hypoxic day-7 LC1
repopulated LC2 with stem-type kinetics, which was largely resistant to BZ added at either time 0 or day 1, indicating that
hypoxia-selectable stem cells are BZ-resistant per se, i.e. before their selection. Furthermore, these cells were completely
resistant to day-6 BZ, i.e. after selection. On the other hand, hypoxia-selected stem cells from CD34-positive cells of blast-
crisis CML patients appeared completely resistant to either time-0 or day-1 BZ. To exploit in vitro the capacity of CML cells to
adapt to hypoxia enabled to detect a subset of BZ-resistant leukemia stem cells, a finding of particular relevance in light of
the fact that our experimental system mimics the physiologically hypoxic environment of bone marrow niches where
leukemia stem cells most likely home and sustain minimal residual disease in vivo. This suggests the use of BZ as an
enhanced strategy to control CML. in particular to prevent relapse of disease, to be considered with caution and to need
further deepening.
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Introduction
We previously demonstrated that severe hypoxia inhibits growth
of leukemia cell populations and selects cells exhibiting properties
of leukemia stem cells (LSC) [1–3]. Incubation of Chronic Myeloid
Leukemia (CML) cells in hypoxia, including K562 as well as the
corresponding primary cells (from blast-crisis patients), results in
the complete suppression of BCR/Abl protein, but not mRNA, so
that hypoxia-selected CML stem cells, while remaining genotyp-
ically leukemic, are phenotypically independent of BCR/Abl
signaling and thereby refractory to the treatment with Imatinib-
mesylate (IM) [1,3]. This is very well in keeping with the notions
that IM, despite its impressive efficacy as first-line therapy for
patients with chronic phase CML, induces a state of minimal
residual disease (MRD), rather than cure, and that LSC are the
source of MRD. On this basis, we proposed that LSC responsible
for MRD of CML home in vivo within severely hypoxic areas of
bone marrow [3] where normal hematopoietic stem cells
physiologically reside (the hypoxic stem cell niches) [4–7]. Thus,
strategies to target IM-refractory LSC of CML are worth being
explored within this context, taking advantage of LSC selection in
hypoxia prior to drug administration in vitro to mimic the impact of
treatment on cells already adapted to home in hypoxic tissue areas
in vivo.
CML treatment with Bortezomib (BZ), a specific and reversible
inhibitor of proteasome activity which is licensed for clinical use in
mantle cell lymphoma and multiple myeloma, is being proposed to
target LSC [8], on the basis of data indicating that BCR/Abl
expression results in increased proteasome activity and that
proteasome inhibition is cytotoxic against CML cell lines [9].
The study reported here addressed the effects of BZ on K562 as
well as primary CML cells in severe hypoxia, to assess the
sensitivity to BZ of hypoxia-selected LSC independently of, and in
comparison with, that of unselected cells.
The quality of LSC selection, as well as the effects of BZ on
hypoxia-selected LSC, were determined by the Culture-Repopu-
lating Ability (CRA) assay, a simple and effective method to test in
vitro the effects of drugs on LSC. This assay measures the stem cell
potential in growth-inhibitory ‘‘selection’’ primary cultures (LC1)
by determining the capacity of cells at the end of LC1 to
repopulate growth-permissive ‘‘expansion’’ secondary cultures
(LC2) and evaluating the kinetics of this repopulation. Further
advantage to our experimental strategy is given by the fact that
hypoxia selects LSC from every leukemia cell population tested so
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enables to work with relatively high numbers of hypoxia-selected
cells and to reduce the complexity of system, as exogenous
cytokines are necessary to support survival and growth of primary
cells. Yet, data gathered with cell lines are of value for preclinical
purposes, given their consistency with those obtained for primary
cells and reported in this paper and earlier [3].
Results
K562 cell cultures were treated or not with a single dose of BZ
from time 0 or day 1 to day 7. BZ addition to hypoxic cultures at
time 0 markedly reduced the number of viable cells throughout
incubation (Figure 1A), producing results comparable to those
determined in normoxia (Figure 1B). On the contrary, BZ
treatment at day 1 of hypoxic, but not normoxic, cultures was
completely ineffective. It is worth pointing out that a 24-hour
treatment with BZ in hypoxia yielded different results whether it
was applied from time 0 to day 1 or from day 1 to day 2, an
outcome indicating that a one-day pre-incubation in hypoxia
protects cell bulk from the effects of BZ.
The hypoxia-dependent protection from the effects of BZ was
confirmed by the marked early activation of caspase-3 and
induction of apoptosis which followed BZ addition at time 0, but
not day 1 (Figure 2), suggesting that hypoxia interfered with BZ by
preventing caspase-dependent apoptosis of cell bulk [10]. At later
incubation times, as expected [2,3], hypoxia per se induced
apoptosis in most cells.
Figure 3 shows that time-0 BZ markedly accelerated BCR/
Ablprotein suppression occurring in untreated hypoxic cultures
[1,3], where BCR/Ablprotein was still well expressed at day 2. BZ
treatment at day 1 failed to determine such an effect, indicating
that a one-day incubation in hypoxia protected BCR/Ablprotein
from BZ-induced suppression. When compared to time-0 BZ, day-
1 BZ was not just ineffective, but actually delayed BCR/Ablprotein
suppression, indicating that hypoxia suppressed BCR/Ablprotein at
least in part via proteasoma.
The effects of BZ in hypoxia or normoxia on leukemia
progenitor and stem cells were then determined by the CRA
assay [1–3,11]. Cells treated or not with BZ in hypoxic LC1 were
transferred at different times of incubation therein into BZ-free
normoxic LC2 to determine the pattern of their repopulation.
Cells replated from day-2 hypoxic LC1, where hypoxia-dependent
cell selection had not occurred yet and BCR/Ablprotein was still
expressed [1,3], rapidly repopulated LC2, to peak at day 10, as an
effect of BCR/Abl-dependent growth stimulation (Figure 4A). BZ
addition to hypoxic LC1 at day 1 did not alter this kinetics
significantly, in keeping with the fact that day-1 BZ did not
suppress BCR/Ablprotein (see Figure 3). BZ addition to hypoxic or
normoxic LC1 at time 0 (or to normoxic LC1 at day 1; data not
shown) abolished LC2 repopulation.
On the other hand, cell transfer to LC2 from day-7 LC1, i.e.
following a one-log reduction of cell number in LC1 and the
relative enrichment of BCR/Ablprotein-negative cells (see
Figures 1A and 3) [1,3], resulted in a delayed LC2 repopulation,
which reached its peak at day 21 (Figure 4B). Such a kinetics
typically reflects the content of transplanted LC1 cells with LSC
[2,3], as well as normal hematopoietic stem cells [11,12]. LC2
repopulation was significantly reduced, but not abolished, by BZ
addition to hypoxic LC1 at either time 0 or day 1. BZ addition to
normoxic LC1 at time 0 (or day 1; data not shown) abolished
LC2 repopulation. The identical effects of time-0 and day-1 BZ
administered in hypoxia indicated that LSC are in part capable per
se (i.e. before their adaptation to, and enrichment in, hypoxia) to
stand BZ action. To exploit such a resistance, however, LSC are
required to be maintained in hypoxia, as BZ addition to normoxic
LC1 abolished LC2 repopulation by either day-7 or day-2 LC1
cells. On the other hand, when hypoxic LC1 were treated with BZ
at day 6 (i.e. after cell adaptation to, and enrichment in, hypoxia),
LC2 repopulation resulted completely drug-insensitive (Figure 5).
This indicated that LSC, once decisively selected in hypoxia, are
completely resistant to BZ.
While we were completing our study, the effects of higher BZ
doses, although for shorter times than in our experiments, were
published [8]. When we tested, on this basis, the effects of the
addition of 5–20 nM BZ to hypoxic LC1 at day 1, BZ was
completely ineffective in either LC1 or LC2 (data not shown),
indicating that a 24-hour pre-incubation in hypoxia confers
resistant also to high-dose BZ.
Figure 1. Effects of Bortezomib (BZ) on K562 cell bulk. Cultures were treated or not with a single dose of 0.5 nM BZ from time 0 to day 7 or
from day 1 to day 7 and trypan blue-negative cells counted at the indicated times. Values represent means6S.E.M. of data from 3 independent
experiments. (A): hypoxia (,0.1% O2); (B): normoxia (21% O2).
doi:10.1371/journal.pone.0017008.g001
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indicated antibodies. Anti-H4 was used to verify equalization of protein loading. One representative experiment out of 3 is shown. (B) Percentages
cells undergone ‘‘early’’ (annexin-V+/PI-) or ‘‘late’’ (annexin-V+/PI+) apoptosis, as determined by flow-cytometry. Values are means6S.E.M. of 3
independent experiments.
doi:10.1371/journal.pone.0017008.g002
Figure 3. Effects of BZ on BCR/Abl protein expression in hypoxia. Total cell lysates in Laemmli buffer were subjected to immuno-blotting
with an anti-Abl antibody. Anti-vinculin and anti-ERK1/2 antibodies were used to verify equalization of protein loading. One representative
experiment out of 3 is shown.
doi:10.1371/journal.pone.0017008.g003
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bone marrow cells explanted from blast-crisis CML patients. BZ
enhanced the hypoxia-induced time-dependent reduction of the
number of viable cells in LC1, irrespective of whether had been
added at time 0 or day 1 (Figure 6A), the effect of time-0 BZ being
perhaps faster (see day 2). CML cells from day-7 hypoxic LC1
repopulated normoxic LC2 reaching peak after 4 weeks of
incubation. LC2 repopulation was not consistently affected by
BZ treatment of LC1 at either time 0 or day 1 (Figure 6B). LC2
repopulation was paralleled by re-expression of BCR/Ablprotein
(data not shown), as expected [1,3]. Thus, primary CML cells were
found to contain hypoxia-selectable LSC completely resistant to
BZ.
Discussion
This study showed, in primary as well as K562 CML cells,
differences with respect to response to BZ between cell bulk
(sensitive) and a cell subset containing LSC selected following
prolonged incubation in hypoxia (resistant). Two different ways for
CML cells to adapt to hypoxia were also evidenced: a ‘‘rapid
adaptation’’ (occurring within 1 day of incubation in hypoxia) of
cell bulk emerged, capable to prevent BZ-induced caspase
activation, apoptosis and BCR/Ablprotein suppression, and the
consequent destruction of culture. Such a rapid adaptation to
hypoxia was not necessary for a minority of cells suitable to survive
independently of BCR/Ablprotein expression and thereby undergo
selection through 7 days of incubation in hypoxia. These cells were
in large part BZ-insensitive during their selection irrespective of
time (time 0 or day 1) of drug addition (see Figure 4B), and
completely insensitive to BZ treatment after cell selection in
hypoxia (at day 6; Figure 5). Thus, a leukemia cell subset exists
which is predisposed to exhibit a stem cell phenotype and to
escape hypoxia-induced apoptosis, so that it can then undergo a
relatively slow program of adaptation to hypoxia, which
progressively consolidates BZ resistance.
The most relevant result of this study is that hypoxia-adapted
LSC of blast-crisis CML are completely resistant to BZ. This
resistance, if one assumes hypoxia-adapted LSC to be a subset of
total LSC, is likely to explain why BZ was found to determine a
marked decline of BCR/Abl-positive chronic-phase LSC, but not
their eradication [8]. We believe the hypoxia-adapted LSC subset
to be the main source of MRD, as it is adapted to home in the
physiologically hypoxic stem cell niches of bone marrow [4–7,13].
Under this perspective, the more interesting results reported here
are those obtained following BZ treatment at day 1 (as well as day
6) of incubation in hypoxia, as they mimic more realistically what
Figure 4. Effects of BZ on hypoxia-resistant K562 cell subsets. Cells treated as indicated in hypoxic or normoxic LC1 (established at 3610
4
viable cells/ml) were transferred at day 2 (A) or day 7 (B) into normoxic LC2 (3610
4 viable cells/ml) and trypan blue-negative cells counted at the
indicated times of incubation in LC2. Values represent means6S.E.M. of data from 3 independent experiments.
doi:10.1371/journal.pone.0017008.g004
Figure 5. Effects of BZ on hypoxia-selected K562 cells. Cells from
day-7 hypoxic LC1 treated with BZ at day 6 as indicated were transferred
into normoxic LC2 (3610
4 viable cells/ml) and trypan blue-negative cells
counted at the indicated times of incubation in LC2. Values represent
means6S.E.M. of data from 3 independent experiments.
doi:10.1371/journal.pone.0017008.g005
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placed in hypoxic tissue areas.
The demonstration that hypoxia-selected LSC of CML, which
we previously showed to be refractory to IM [1,3], are also
resistant to BZ needs to be discussed in view of the possible
development of a BZ/IM combination protocol for treatment of
CML. Our results indicated that there is no point in using BZ to
target hypoxia-selected, BCR/Ablprotein–negative LSC. On the
other hand, we also showed (see above) that K562 cell bulk can
acquire resistance to BZ via a rapid program of adaptation to
hypoxia. As this occurs while cells are still IM-sensitive due to the
maintained expression of BCR/Ablprotein, there is no apparent
advantage either for using BZ together with IM to target BCR/
Ablprotein–expressing cells. Taken together, our results suggest the
use of BZ as an enhanced strategy to control CML to be
considered with caution and to need further deepening, especially
considering the known toxic effects of BZ, including myelosup-
pression [8].
Materials and Methods
Cells and culture conditions
K562 and primary CML cells were routinely cultured in RPMI
1640 medium supplemented with 10% foetal bovine serum, 50
units/ml penicillin and 50 mg/ml streptomycin (all from Euro-
Clone, Paington, UK, E.U.). Primary CML cells were collected
after informed consent to the use for basic in vitro research,
according to the Helsinki declaration and following approval of
the Ethics Committee, at the Division of Hematology of Universita `
di Firenze. CD34-positive cells were cultured in the presence of
Flt-3 ligand (50 ng/ml) TPo (20 ng/ml) and SCF/KL (50 ng/ml)
in LC1 and of SCF (50 ng/ml), G-CSF (100 ng/ml), IL-6 (20 ng/
ml) and IL3 (10 ng/ml) in LC2 (all from PeproTech, Rocky Hill,
NJ, U.S.A.). Exponentially growing cells were plated at 3610
5/ml
and incubated in hypoxia (,0.1% O2) in a Concept 400 anaerobic
incubator (Ruskinn Technology Ltd., Bridgend, UK, E.U.) or
normoxia (21% O2), at 37uC in a water-saturated atmosphere
containing 0.1% O2, 94.9% N2 and 5% CO2.
Reagents
Bortezomib (VelcadeH, Millennium Pharmaceuticals, Cam-
bridge, MA, U.S.A.) was added to cultures at 0.5 nM (cell lines
and primary cells) at the indicated times.
Measurement of cell viability and apoptosis
Viable cells were counted in a hemocytometer by trypan blue
exclusion. Apoptotic cells were detected by using a FACSCanto
flow-cytometer (Becton & Dickinson, Franklin Lakes, NJ, U.S.A.),
after staining with FITC-conjugated annexin V and propidium
iodide (PI), using the Annexin V-fluos staining kit (Roche
Diagnostics, Basel, Switzerland) and following manufacturer’s
instructions. The percentages of annexin-V+/PI- or annexin-V+/
PI+ cells are considered to reflect ‘‘early’’ or ‘‘late’’ apoptosis.
The CRA assay. This assay estimates the culture-
repopulating power of normal [11,12] or leukemic [1–3]
hematopoietic cells undergone a selection treatment (e.g.
hypoxia) in a primary liquid culture (LC1) by means of their
transfer in fresh medium to non-selective conditions (e.g.
normoxia) in a growth-permissive secondary culture (LC2) and
the measure of its repopulation following a further incubation
therein. Cell subsets rescued from LC1 at different times
repopulate LC2 with different kinetics, the time necessary to
reach the peak of LC2 repopulation reflecting the hierarchical
level of stem/progenitor cells enriched in LC1. The CRA assay is
a non-clonogenic assay capable to reveal in vitro stem cells endowed
with marrow-repopulating ability in vivo [11]. The adaptation of
CRA assay to leukemia cell populations enabled to detect different
subsets of leukemia stem or progenitor cells [1–3].
Figure 6. Effects of BZ on hypoxia-resistant primary CML cells. Immunomagnetically-selected CD34+ bone marrow cells from 3 blast-crisis
CML patients were treated in hypoxic LC1 (established at 3610
4 viable cells/ml) as indicated (A) and transferred at day 7 into normoxic LC2 (3610
4
viable cells/ml) (B), where trypan blue-negative cells were counted at the indicated times of incubation. Values represent means6S.E.M. of data from
3 independent experiments.
doi:10.1371/journal.pone.0017008.g006
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Cells (5610
6) were washed twice with ice-cold PBS containing
Na3VO4 100 mM and solubilyzed by incubating for 10 min at
95uC in Laemmli buffer (Tris/HCl 62.5 mM, pH 6.8, 10%
glycerol, 0.005% blue bromophenol, 2% SDS). Lysates were
clarified by centrifugation (20000 g, 10 minutes, RT) and protein
concentration in supernatants was determined by the BCA
method. Aliquots (30 mg/sample) were boiled for 10 min in the
presence of 100 mM 2-mercaptoethanol, subjected to SDS-PAGE
in 7.6% polyacrylamide minigels and then transferred onto PVDF
membranes (Millipore Corporate, Billerica, MA, U.S.A.) by
electroblotting. Membranes were blocked in Odyssey Blocking
Buffer (OBB)/PBS (1:1) for 1 hour at RT and incubated in a
1:1000 dilution of antibody in PBS 0,1% Tween (T-PBS)/OBB
(1:1) overnight at 4uC. Primary (all rabbit) antibodies were: anti-c-
Abl and anti-cleaved-caspase 3 (from Cell Signaling Technology,
Danvers, MA, U.S.A.), anti-caspase 3 and anti-ERK-1/2 (from
Santa Cruz Biotechnology, S. Cruz, CA, U.S.A.), anti-H4 (from
Millipore, Billerica, MA, U.S.A.) and anti-vinculin (from Sigma-
AldrichH, St. Louis, MO, U.S.A.). Secondary anti-IgG antibodies
were IRDyeH800CW- or IRDyeH680-conjugated (LI-CORH
Biosciences, Lincoln, NE, U.S.A.). Antibody-coated protein bands
were visualized by the Odyssey Infrared Imaging System
Densitometry (LI-CORH).
Statistical Analysis
All experiments were performed in triplicate or higher numbers
of repeats. Statistical significance was evaluated by Student’s t-test
for paired samples; p values ,.05 (two-sided) were considered
statistically significant.
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